David R. Wise, MD, PhD, discusses the potential for pasritamig combined with docetaxel to improve outcomes in patients with mCRPC.
David R. Wise, MD, PhD
Advertisement
Articles by David R. Wise, MD, PhD
David R. Wise, MD, PhD, highlights initial findings from a phase 1b study of pasritamig plus docetaxel in patients with metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
David Wise, MD, outlines early data on pasritamig in mCRPCFebruary 28th 2026
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
3
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5